Compare Stocks → This company has increased its dividend every year for 54 years (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNASDAQ:ALNANASDAQ:BVXVNASDAQ:KRBPNASDAQ:MBOT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$11.75$0.61▼$24.20$820K1.4119,299 shs416,900 shsALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsKRBPKiromic BioPharma$2.30-21.0%$2.61$0.16▼$8.97$2.96M28,696 shs15,369 shsMBOTMicrobot Medical$0.90-5.3%$1.21$0.88▼$4.37$12.96M1.64123,500 shs237,812 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%-35.20%-94.67%-96.02%-93.59%ALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%-36.74%KRBPKiromic BioPharma+3.56%+28.19%+95.96%+45.50%-39.38%MBOTMicrobot Medical-7.88%-16.04%-14.52%-24.70%-47.58%Don’t expose yourself to stocks during the week (Ad)The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.Click here and I’ll give you all the details.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AMBOTMicrobot Medical1.4371 of 5 stars3.53.00.00.02.20.80.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AMBOTMicrobot Medical3.00Buy$7.00677.78% UpsideCurrent Analyst RatingsLatest ACOR, BVXV, KRBP, ALNA, and MBOT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.00(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00ALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/AKRBPKiromic BioPharmaN/AN/AN/AN/A($7.25) per shareN/AMBOTMicrobot MedicalN/AN/AN/AN/A$0.38 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%5/9/2024 (Estimated)ALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/ABVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/AKRBPKiromic BioPharma-$20.95M-$15.07N/A∞N/AN/AN/A-125.75%N/AMBOTMicrobot Medical-$10.74M-$1.08N/A∞N/AN/A-164.13%-125.22%5/15/2024 (Estimated)Latest ACOR, BVXV, KRBP, ALNA, and MBOT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023KRBPKiromic BioPharmaN/A-$4.16-$4.16-$4.16N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26ALNAAllena PharmaceuticalsN/A1.581.58BVXVBiondVax PharmaceuticalsN/A4.124.12KRBPKiromic BioPharmaN/A0.220.22MBOTMicrobot MedicalN/A2.092.09OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%ALNAAllena Pharmaceuticals7.33%BVXVBiondVax Pharmaceuticals11.83%KRBPKiromic BioPharma10.91%MBOTMicrobot Medical16.30%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%ALNAAllena Pharmaceuticals3.70%BVXVBiondVax Pharmaceuticals6.03%KRBPKiromic BioPharma3.25%MBOTMicrobot Medical10.64%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableKRBPKiromic BioPharma351.29 million1.25 millionNot OptionableMBOTMicrobot Medical1814.40 million12.87 millionOptionableACOR, BVXV, KRBP, ALNA, and MBOT HeadlinesSourceHeadlineMicrobot Medical (NASDAQ:MBOT) Price Target Cut to $7.00 by Analysts at HC Wainwrightamericanbankingnews.com - April 17 at 3:48 AMAnalysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)markets.businessinsider.com - April 16 at 5:45 PMMicrobot Medical Shares Status Following Recent Geopolitical Eventsglobenewswire.com - April 15 at 8:30 AMMicrobot Medical Inc. (NASDAQ:MBOT) Short Interest Updateamericanbankingnews.com - April 12 at 4:26 AMMicrobot Medical (NASDAQ:MBOT) & Alpha Tau Medical (NASDAQ:DRTS) Financial Analysisamericanbankingnews.com - April 9 at 4:16 AM3 AI Stocks Wall Street Expects to Return Up to 595% in 2024msn.com - March 28 at 10:05 AMMBOT Stock Earnings: Microbot Medical Misses EPS for Q4 2023investorplace.com - March 27 at 11:03 PMMBOT Apr 2024 3.000 callca.finance.yahoo.com - March 16 at 10:15 AMMicrobot Medical Stock (NASDAQ:MBOT) Dividends: History, Yield and Datesbenzinga.com - February 26 at 1:07 AMMBOT Jul 2024 2.500 putfinance.yahoo.com - February 21 at 2:27 AMMBOT Apr 2024 5.000 callfinance.yahoo.com - February 21 at 2:27 AMMBOT Mar 2024 2.500 callfinance.yahoo.com - February 18 at 3:16 PMMicrobot Medical Inc.: Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the USfinanznachrichten.de - February 5 at 12:27 PMMicrobot Medical submits surgical robot for FDA IDEmassdevice.com - February 5 at 12:27 PMMicrobot files FDA application for clinical study of Liberty systemmsn.com - February 5 at 12:27 PMMicrobot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the USfinance.yahoo.com - February 5 at 12:27 PMLooking Into Microbot Medical's Recent Short Interestbenzinga.com - February 2 at 1:43 PMMicrobot Medical Settles: Regulation FD Disclosure Updatemsn.com - January 31 at 6:41 PMMicrobot Medical Inc.: Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Mattersfinanznachrichten.de - January 30 at 4:59 PMMicrobot Medical announces settlement resolving legal mattersmsn.com - January 30 at 9:28 AMMicrobot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Mattersfinance.yahoo.com - January 30 at 9:28 AMMicrobot Medical expands U.S. operations to prep for first in-human clinical studytherobotreport.com - January 24 at 12:41 PMMicrobot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Studyfinance.yahoo.com - January 18 at 10:30 AMMicrobot Medical Shares Drop 20% After Exercising Investment Optionsmarketwatch.com - December 29 at 4:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Allena PharmaceuticalsNASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.BiondVax PharmaceuticalsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Kiromic BioPharmaNASDAQ:KRBPKiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.Microbot MedicalNASDAQ:MBOTMicrobot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. In addition, it provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.